Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
United States
/
Pharmaceuticals & Biotech
/
Harrow
HROW
Harrow
Rising Pricing Pressures Will Strain Ophthalmics Yet Foster Cautious Resilience
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
28 Aug 25
Updated
28 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$42.00
7.1% undervalued
intrinsic discount
28 Aug
US$39.00
1Y
-3.6%
7D
-0.3%
Loading
1Y
-3.6%
7D
-0.3%
Author's Valuation
US$42.0
7.1% undervalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$42.0
7.1% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-33m
503m
2014
2017
2020
2023
2025
2026
2028
Revenue US$502.7m
Earnings US$98.3m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
25.36%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$98.26m
Earnings '28
x
21.34x
PE Ratio '28
=
US$2.10b
Market Cap '28
US$2.10b
Market Cap '28
/
41.50m
No. shares '28
=
US$50.52
Share Price '28
US$50.52
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$41.50
Fair Value '25
